Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
Tuberculosis New Vaccine
About Tuberculosis New Vaccine
New tuberculosis vaccines are urgently needed as BCG provides variable protection. M72 AS01E, developed by GSK, showed approximately 50 percent efficacy in a Phase 2b trial reported in 2018 and 2019, one of the most promising TB vaccine results in decades. A Phase 3 trial began in 2024. MTBVAC, a live attenuated vaccine derived from a clinical Mycobacterium tuberculosis strain, entered a Phase 3 efficacy trial in newborns in 2022. An early trial suggested BCG revaccination might protect adolescents against sustained TB infection, but a larger follow up trial did not confirm this. The Bill and Melinda Gates Foundation and the Wellcome Trust are funding the M72 Phase 3 trial. A new TB vaccine could save millions of lives, particularly in high burden countries like India, Indonesia, and South Africa.
Related Entries
Strep A Vaccine
Group A Streptococcus vaccines target Strep A, which causes pharyngitis, skin infections, rheumatic ...
Universal Flu Vaccine
Universal influenza vaccine research aims to develop a vaccine that provides protection against all ...
HIV Vaccine
HIV vaccine research began in 1987 and has been one of the most challenging fields in vaccinology. H...
Norovirus Vaccine
Norovirus vaccines target the leading cause of acute gastroenteritis. Norovirus causes approximately...